AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...

The primary endpoint was functional immune tolerance, defined as off all immunosuppressive drugs 24 months after ...

Techcyte is proud to share results from a published pilot study demonstrating the effectiveness of its AI-powered kidney ...

Recurrent lupus nephritis post-transplant may go undetected without surveillance biopsies. This study reveals high recurrence ...

In comparative analysis, EchoGo® Amyloidosis outperformed two validated clinical scoring systems, the Transthyretin Cardiac ...

ApoCII amyloidosis, resulting from abnormal organ deposition of toxic fibrillar amyloid proteins, is an ultra-rare condition that mostly affects the kidneys and manifests with protein spillage into th ...

Among 83 patients receiving biologic agents for their underlying conditions and who had serum amyloid-α (AA) amyloidosis affecting the kidneys, from 60% to 88% did not develop end-stage renal ...

About AL Amyloidosis AL amyloidosis is caused by abnormal plasma cells in the bone marrow, which produce misfolded amyloid proteins that circulate in the blood, then build-up in the heart, kidney, ...

NIJMEGEN, Netherlands & CAMBRIDGE, Mass.-- (BUSINESS WIRE)-- Aiosyn, a pioneering pathology software company specializing in AI-powered solutions for cancer and kidney disease, and Pramana, an ...

 In this retrospective cohort study, decline in kidney function was frequent in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and was consistently associated with an increased ...

Bone marrow biopsy revealed 2% lambda restricted plasma cells without evidence of amyloid deposits; metastatic bone survey was negative. A fat pad biopsy and endomyocardial biopsy stained negative for ...

In this population-based study, which included more than 16,000 kidney-allograft biopsy specimens, we observed that the clinical recognition of microvascular inflammation in kidney allografts ...